LTZ Therapeutics develops myeloid engager therapeutics that directly activate myeloid cells to enhance anti-tumor immunity and reprogram the immunosuppressive tumor microenvironment. This approach addresses the unmet clinical needs in cancer treatment by improving the efficacy and safety of immunotherapy through targeted engagement of tumor-specific T cells.
Funding
$47.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LCFounders
Product
Problem
Current cancer immunotherapies often fail to provide sufficient efficacy and safety due to the immunosuppressive nature of the tumor microenvironment and the limited activation of myeloid cells. Existing approaches struggle to effectively reprogram the tumor microenvironment and enhance anti-tumor immunity through targeted engagement of tumor-specific T cells.
Solution
LTZ Therapeutics is developing a novel class of myeloid engager therapeutics designed to directly activate myeloid cells, such as macrophages, to enhance anti-tumor immunity and reprogram the immunosuppressive tumor microenvironment. This approach leverages reverse translational science and emerging biology of the tumor microenvironment to improve clinical benefits. LTZ's myeloid engager platform facilitates the direct engagement of myeloid cells with target cells, activating killing mechanisms like phagocytosis. The platform stimulates myeloid cells to release minimal cytokines and chemokines, which reprograms the tumor microenvironment and enhances cytotoxic T cell function. The platform also supports cross-presentation of tumor neoantigens and activation of tumor-specific T cells to support durable anti-tumor immune responses and immunological memory.
Target Audience
The primary target audience includes oncology researchers and clinicians focused on developing and applying immunotherapies for cancer and autoimmune diseases.
Features
- Myeloid engager platform for direct engagement of myeloid cells with target cells
- Activation of killing mechanisms, such as phagocytosis, by myeloid cells
- Stimulation of myeloid cells to release minimal cytokines and chemokines
- Reprogramming of the immunosuppressive tumor microenvironment
- Enhancement of cytotoxic T cell function
- Cross-presentation of tumor neoantigens
- Activation of tumor-specific T cells to support durable anti-tumor immune responses and immunological memory